SCHEMBL720162

SCHEMBL720162

CC(=O)c1ncccc1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN2 Q96KS0 1/20 0.51
FTO Q9C0B1 1/20 0.51
TLR7 Q9NYK1 5/20 0.49
ALDH1A1 P00352 3/20 0.47
THRB P10828 1/20 0.46
KDM4E B2RXH2 4/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
TSHR P16473 2/20 0.45
MAPT P10636 2/20 0.45
CYP3A4 P08684 1/20 0.45
ALOX15 P16050 1/20 0.45
BLM P54132 1/20 0.45
AGER Q15109 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
SPR P35270 1/20 0.44
MMP2 P08253 1/20 0.42
CHRM1 P11229 1/20 0.42
COMT P21964 1/20 0.42
ADRA1A P35348 1/20 0.42
METAP2 P50579 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5713031 0.82 EGLN2 (0.46) EGLN2FTOTLR7ALDH1A1KDM4E
SCHEMBL27699633 0.82 FTO (0.55) EGLN2FTOTLR7ALDH1A1KDM4E
Methyl Alcohol SCHEMBL28038357 0.81 KDM4E (0.59) EGLN2FTOTLR7ALDH1A1KDM4E
SCHEMBL29543454 0.81 ALDH1A1 (0.45) EGLN2FTOTLR7ALDH1A1KDM4E
SCHEMBL5313640 0.81 ALDH1A1 (0.45) EGLN2FTOTLR7ALDH1A1KDM4E
SCHEMBL15312235 0.80 KDM4E (0.63) EGLN2FTOTLR7ALDH1A1KDM4E
SCHEMBL78249 0.80 KDM4E (0.63) EGLN2FTOTLR7ALDH1A1KDM4E
SCHEMBL31356480 0.80 KDM4E (0.63) EGLN2FTOTLR7ALDH1A1KDM4E
SCHEMBL2277608 0.78 KDM4E (0.61) EGLN2FTOTLR7ALDH1A1KDM4E
SCHEMBL1985357 0.78 KDM4E (0.61) EGLN2FTOTLR7ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4355748-B1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2026-05-13 EP disclosed
US-20250171462-A1 COMPOUNDS, COMPOSITIONS, AND METHODS TENVIE THERAPEUTICS, INC. 2025-05-29 US disclosed
WO-2025008288-A1 9-OXO-9,10-DIHYDRO-6H-PYRANO[3,2-B:4,5-B']DIPYRIDINE-8-CARBOXYLIC ACID DERIVATIVES CENTENARA LABS AG (CH) 2025-01-09 WO disclosed
EP-4486722-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Nico Therapeutics, Inc. (US) 2025-01-08 EP disclosed
CN-119137101-A Compounds, compositions, and methods 尼科治疗有限公司 2024-12-13 CN disclosed
US-20240383901-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2024-11-21 US disclosed
CN-112823157-B Spirochroman derivatives 吉瑞工厂 2024-08-09 CN disclosed
EP-4355748-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2024-04-24 EP disclosed
US-11964986-B1 9-oxo-9,10-dihydro-6H-pyrano[3,2-b:4,5-b′]dipyridine-8-carboxylic acid derivatives REJUVERON TELOMERE THERAPEUTICS AG (CH) 2024-04-23 US disclosed
CN-117384124-A HDAC inhibitors, compositions and uses thereof 安徽中医药大学 2024-01-12 CN disclosed
WO-2005069981-A2 METHOD OF PREPARATION OF BENZOFURAN-2-CARBOXYLIC ACID {(S)-3-METHYL-1-[(4S, 7R)-7METHYL-3-OXO-1-(PYRIDINE-2-SULFONYL)-AZEPAN-4-YLCARBAMOYL]-BUTYL}-AMIDE SMITHKLINE BEECHAM CORPORATION (US) 2005-08-04 WO disclosed
EP-0362771-B1 Use of photochromic substances RODENSTOCK OPTIK G (DE) 2000-05-31 EP disclosed
US-5637709-A Photochromatic substances OPTISCHE WERKE G. RODENSTOCK (DE) 1997-06-10 US disclosed
US-5608065-A ADAMANTANEOSPIRO-HETEROAROMATIC PYRANS OPTISCHE WERKE G. RODENSTOCK (DE) 1997-03-04 US disclosed
EP-0470391-B1 Use of pyridines as perfume or aroma ingredients FIRMENICH & CIE (CH) 1995-08-23 EP disclosed
EP-0308792-B1 AZACHROMANE DERIVATIVES MERCK PATENT GmbH (DE) 1993-07-28 EP disclosed
US-4931454-A Azachroman derivatives with effects on the cardiovascular system MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1990-06-05 US disclosed
EP-0362771-A1 Photochromic substances Optische Werke G. Rodenstock (DE) 1990-04-11 EP disclosed
WO-1990003379-A1 PHOTOCHROMIC SUBSTANCES OPTISCHE WERKE G. RODENSTOCK (DE) 1990-04-05 WO disclosed
EP-0308792-A2 Azachromane derivatives MERCK PATENT GmbH (DE) 1989-03-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383901-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION LRRK2, PARK7, SNCA EGLN2 3850/4885FTO 2687/4885TLR7 2227/4885
US-20250171462-A1 COMPOUNDS, COMPOSITIONS, AND METHODS SARM1, SARS1, TIAM1 EGLN2 2989/4885FTO 2824/4885TLR7 3738/4885
US-11964986-B1 9-oxo-9,10-dihydro-6H-pyrano[3,2-b:4,5-b′]dipyridine-8-carboxylic acid derivatives DPP9, DPYD, QDPR EGLN2 1410/4885FTO 1966/4885TLR7 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.